In vivo peptide therapy

Details In vivo peptide therapy In vivo peptide therapy

C - Chemistry, Metallurgy

07

H

C07H 21/00 (2006.01) A61K 31/70 (2006.01)

Patent

CA 2134237

2134237 9318794 PCTABS00025 Method for treatment of a patient having a normal level of activity of a naturally occurring protein, or having a condition characterized by the presence of an elevated or reduced level of that natural protein. The method includes administering to the patient nucleic acid which encodes an agonist or inhibitory polypeptide of the biological activity of the natural protein, or of a naturally occurring effector which affects the biological activity of that natural protein. The agonist or inhibitor is a polypeptide (i.e. an amino acid chain including at least 2 amino acids, and generally up to about 500 amino acids) expressed from the nucleic acid when that nucleic acid is present in the patient. This agonist and inhibitory polypeptide act in vivo to increase or reduce respectively the specific biological activity of the natural protein or the naturally occurring effector in the patient.

Affiliated with

Also associated with

Rating

In vivo peptide therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with In vivo peptide therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In vivo peptide therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1572400